Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In science as in life, the language we choose to use is of great importance and power. This is particularly true in discussion of medical conditions. More care is needed to sensitively discuss diseases and patient care.
Advances in hepatitis B management are still not reaching most of the affected community. A major barrier to this translation is stigma. Research and clinical communities have a responsibility to mitigate stigma and ensure that the voices of the affected community are considered in decision-making conversations.
This Review covers the discovery of Akkermansia muciniphila and its association with health and disease, including metabolic diseases. Insights into underlying mechanisms for how A. muciniphila improves health are given as are comparisons with other next-generation beneficial microorganisms.
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is a chronic liver disease typically associated with obesity. This Review discusses the epidemiology and physiology of individuals of normal weight with MAFLD and provides insights into their metabolic health and metabolic adaptation.
Diet is part of the multidisciplinary management of inflammatory bowel disease (IBD). This Review outlines a step-based approach to the dietary management of IBD, outlining the role of dietary therapy with practical insights for dietitians and clinicians.
Surveillance of hepatocellular carcinoma (HCC), one of the most lethal solid cancers globally, is insensitive for the detection of early-stage tumours. In this Review, the authors discuss HCC biomarkers that can improve early diagnosis, therapy monitoring and prediction of therapy response.
